EA200300028A1 - TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH HEART INSULIN RESISTANCE - Google Patents

TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH HEART INSULIN RESISTANCE

Info

Publication number
EA200300028A1
EA200300028A1 EA200300028A EA200300028A EA200300028A1 EA 200300028 A1 EA200300028 A1 EA 200300028A1 EA 200300028 A EA200300028 A EA 200300028A EA 200300028 A EA200300028 A EA 200300028A EA 200300028 A1 EA200300028 A1 EA 200300028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
insulin resistance
conditions associated
prevention
treatment
pharmaceutically acceptable
Prior art date
Application number
EA200300028A
Other languages
Russian (ru)
Inventor
Амит Натвани
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200300028A1 publication Critical patent/EA200300028A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Описан способ лечения и/или профилактики сердечной инсулинорезистентности или состояний, ассоциированных с сердечной инсулинорезистентностью, у человека или млекопитающих, не относящихся к человеку, включающий введение эффективного нетоксичного и фармацевтически приемлемого количества агониста PPARγ, такого как соединение (I) или его фармацевтически приемлемого производного. Состояниями, ассоциированными с сердечной инсулинорезистентностью, являются микроваскулярная стенокардия, атеросклероз и застойная сердечная недостаточность. Указанными соединениями являются розиглитазон, троглитазон, энглитазон и пиоглитазон.Международная заявка была опубликована вместе с отчетом о международном поиске.A method for treating and / or preventing cardiac insulin resistance or conditions associated with cardiac insulin resistance in humans or non-human mammals is described, comprising administering an effective non-toxic and pharmaceutically acceptable amount of a PPARγ agonist, such as compound (I) or a pharmaceutically acceptable derivative thereof. The conditions associated with cardiac insulin resistance are microvascular angina, atherosclerosis, and congestive heart failure. These compounds are rosiglitazone, troglitazone, englitazone and pioglitazone. The international application was published along with an international search report.

EA200300028A 2000-06-16 2000-06-16 TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH HEART INSULIN RESISTANCE EA200300028A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
EA200300028A1 true EA200300028A1 (en) 2003-04-24

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300028A EA200300028A1 (en) 2000-06-16 2000-06-16 TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH HEART INSULIN RESISTANCE

Country Status (15)

Country Link
EP (1) EP1292301A1 (en)
JP (1) JP2004503499A (en)
CN (1) CN1592620A (en)
AP (1) AP2002002688A0 (en)
BG (1) BG107384A (en)
BR (1) BR0017254A (en)
CA (1) CA2436116A1 (en)
DZ (1) DZ3389A1 (en)
EA (1) EA200300028A1 (en)
HU (1) HUP0301103A2 (en)
IL (1) IL153452A0 (en)
MX (1) MXPA02012619A (en)
NO (1) NO20026000L (en)
WO (1) WO2001095906A1 (en)
YU (1) YU1203A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (en) * 1998-07-21 2004-12-20 Smithkline Beecham Plc THIAZOLIDINEDIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE

Also Published As

Publication number Publication date
CN1592620A (en) 2005-03-09
NO20026000L (en) 2003-02-11
NO20026000D0 (en) 2002-12-13
AP2002002688A0 (en) 2002-12-31
CA2436116A1 (en) 2001-12-20
IL153452A0 (en) 2003-07-06
BG107384A (en) 2003-09-30
MXPA02012619A (en) 2003-04-10
HUP0301103A2 (en) 2003-08-28
YU1203A (en) 2006-05-25
EP1292301A1 (en) 2003-03-19
WO2001095906A1 (en) 2001-12-20
BR0017254A (en) 2004-01-06
JP2004503499A (en) 2004-02-05
DZ3389A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
EA199800626A1 (en) APPLICATION OF PPAR-GAMMA AGONIST FOR THE TREATMENT OF SYNDROME X
DOP2004001052A (en) 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2005034952A3 (en) Isoxazole and isothiazole compounds useful in the treatment of inflammation
NL300282I1 (en) New exendin agonist formulations and method for administration thereof.
EA200400305A1 (en) 2,4,5-triple substituted thiazolyl derivatives and their anti-inflammatory activity
EA200401160A1 (en) Derivatives of thiazole and oxyazole, which modulate the activity of PPAR
EA200101089A1 (en) NEW METHOD OF TREATMENT
EA200300265A1 (en) HINAZOLIN DERIVATIVES AS KINASE INHIBITORS
CR11037A (en) DERIVATIVES OF 4-TETRAZOLIL -4FENYLPIPERIDINE TO TREAT PAIN (DIVISIONAL)
EA200200097A1 (en) IMIDAZOMIDASOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS
ATE464905T1 (en) PHOSPHATE TRANSPORT INHIBITORS
AR079473A2 (en) CRYSTAL COMPOUND OF BENZIMIDAZOL PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND METHOD FOR THE MANUFACTURE OF SUCH COMPOSITION
EA200101133A1 (en) A method for inhibiting the aggregation of amyloid proteins and visualizing amyloid deposits using isindoline derivatives
WO2001052847A8 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
KR870007204A (en) Functionalized peptidyl aminodiol and -triol
AU2001285807A1 (en) Acidic treatment liquid and method of treating copper surfaces
SE9803760D0 (en) Methods to treat and diagnose the restless legs syndrome and the corresponding agents
EA199800139A1 (en) METHOD OF TREATMENT OF ASTENOMA
EA200300028A1 (en) TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH HEART INSULIN RESISTANCE
Gillen et al. Problems associated with the clinical use of proton pump inhibitors
MX9805512A (en) Treatment and prevention of cardiac insulin resistance associated conditions.
EA200000042A1 (en) METHOD OF TREATING DIABETES BY ROSIGLITAZON AND INSULIN
NO20000230L (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and <alfa> glucosidase inhibitor